Table 3.
Associations of combined APOB genotypes and CDH13 haplotypes with survival of NSCLC patients
| Genotypes/Haplotypes | Frequencya | OSb | DSSb | ||||
|---|---|---|---|---|---|---|---|
| Deaths (%) | HR (95% CI) | P | Deaths (%) | HR (95% CI) | P | ||
| APOB, rs1801701_T, C>T | |||||||
| CC | 972 | 663 (68.21) | 1.00 | 594 (61.11) | 1.00 | ||
| CT | 192 | 119 (61.98) | 0.72 (0.59–0.88) | 0.016 | 108 (56.25) | 0.73 (0.60–0.91) | 0.004 |
| TT | 11 | 7 (63.64) | 0.76 (0.36–1.61) | 0.476 | 7 (63.64) | 0.82 (0.39–1.73) | 0.593 |
| Trend test | 0.002 | 0.006 | |||||
| Dominant | |||||||
| CCc | 972 | 663 (68.21) | 1.00 | 594 (61.11) | 1.00 | ||
| CT+TT | 203 | 126 (62.07) | 0.73 (0.60–0.88) | 0.014 | 115 (56.65) | 0.74 (0.60–0.91) | 0.004 |
| Recessive | |||||||
| CC+CT | 1164 | 782 (67.18) | 1.00 | 702 (60.31) | 1.00 | ||
| TT | 11 | 7 (63.64) | 0.82 (0.39–1.72) | 0.593 | 7 (63.64) | 0.87 (0.41–1.84) | 0.720 |
| CDH13 haplotypes | |||||||
| H1 | 938 | 637 (67.91) | 1.00 | 567 (60.45) | 1.00 | ||
| H2 | 431 | 270 (62.65) | 0.77 (0.67–0.89) | 0.0004 | 245 (56.84) | 0.80 (0.69–0.93) | 0.003 |
| H3 | 261 | 178 (68.20) | 0.97 (0.82–1.15) | 0.733 | 164 (62.84) | 1.01 (0.84–1.20) | 0.951 |
| H4 | 236 | 145 (61.44) | 0.78 (0.65–0.94) | 0.008 | 127 (53.81) | 0.79 (0.65–0.96) | 0.019 |
| H5 | 231 | 170 (73.59) | 1.24 (1.05–1.47) | 0.013 | 155 (67.10) | 1.26 (1.05–1.51) | 0.012 |
| H6 | 162 | 117 (72.22) | 1.27 (1.05–1.55) | 0.017 | 105 (64.81) | 1.25 (1.02–1.55) | 0.034 |
| H7 | 91 | 61 (67.03) | 0.94 (0.72–1.23) | 0.653 | 55 (60.44) | 0.93 (0.71–1.24) | 0.633 |
| Combined CDH13 haplotypes | |||||||
| FH | 1957 | 1291 (65.97) | 1.00 | 1158 (59.17) | 1.00 | ||
| UHd | 393 | 287 (73.03) | 1.38 (1.21–1.57) | <0.0001 | 260 (66.16) | 1.36 (1.19–1.56) | <0.0001 |
| NUGHe | |||||||
| 0 | 142 | 84 (59.15) | 1.00 | 77 (54.23) | 1.00 | ||
| 1 | 738 | 492 (66.67) | 1.44 (1.13–1.82) | 0.003 | 439 (59.49) | 1.41 (1.10–1.81) | 0.007 |
| 2 | 295 | 213 (72.20) | 1.93 (1.49–2.50) | <0.0001 | 193 (65.42) | 1.82 (1.43–2.46) | <0.0001 |
| Trend test | <0.0001 | <0.0001 | |||||
| NUGH | |||||||
| 0–1 | 880 | 567 (65.45) | 1.00 | 516 (58.64) | 1.00 | ||
| 2 | 295 | 213 (72.20) | 1.42 (1.21–1.68) | <0.0001 | 193 (65.42) | 1.41 (1.19–1.66) | <0.0001 |
Abbreviations: NSCLC, non-small cell lung cancer; HR, hazards ratio; CI, confidence interval; OS, overall survival; DSS, disease-specific survival; FH: favorable haplotypes; UH: unfavorable haplotypes; NUGH: number of unfavorable genotypes/haplotypes.
Ten missing data were excluded.
Adjusted for age, sex, smoking status, histology, tumor stage, chemotherapy, surgery and principal components.
Unfavorable genotype was APOB rs1801701 CC.
Unfavorable haplotypes were H5 (C-A-T-C) and H6 (T-T-T-T) for CDH13 rs35859010-rs1833970-rs254315-rs425904.
Number of unfavorable genotypes/haplotypes (NUGH) were assigned according to the APOB unfavorable genotype model and CDH13 diplotype. 0 = no APOB rs1801701 CC or CDH13 H5/H6; 1 = one APOB rs1801701 CC or CDH13 H5/H6; 2 = both APOB rs1801701 CC and CDH13 H5/H6.